CMS Open Payments · Program Year 2024
Osteoremedies, LLC
Osteoremedies, LLC reported $396,818.12 across General Payments, Research, and Ownership to 183 physicians and teaching hospitals across 183 transactions.
- $396.8K Above-median payer
- All-tracks total
- 183 Above-median volume
- Transactions
- 183 Above-median reach
- Recipients
- −$21.0K
- General Payments vs PY2023
Osteoremedies, LLC reported $396,818.12 across all CMS Open Payments tracks (General + Research + Ownership) to 183 physicians and teaching hospitals in Program Year 2024 - ranking #825 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $396,818.12, averaging $2.2K per recipient.
How Osteoremedies, LLC's $396.8K all-tracks total breaks down
Osteoremedies, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
14/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer osteoremedies-llc Osteoremedies, LLC
$396.8K · #825/1,925 · 0.0% industry · PY2024
- TOT $396.8K
- RANK #825
- SHARE 0.0%
- TXN 183
- RCP 183
- CAT 3
- GEN $396.8K
- ΔGEN −$21.0K
- TOP1 36.1%
- PY 2024
Volume peers
Nearest volume peer: Dentsply LLC ($397.9K)
Osteoremedies, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Osteoremedies, LLC's CMS-reported General Payments decreased by $21.0K (−5.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OSTEOREMEDIES, LLCPY2023: OSTEOREMEDIES, LLCPY2024: Osteoremedies, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $417,859.62
- PY2024
- $396,818.12
What the Data Shows for Osteoremedies, LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Osteoremedies, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
29 transactions worth $359.7K make "Royalty or License" the top general-payment category in the 3-category breakdown below, 90.7% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Osteoremedies, LLC made 3 types of general payments. "Royalty or License" is the largest category at $359.7K, 90.7% of General Payments.
How Osteoremedies, LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $359.7K | 29 | 90.7% |
| Consulting Fee | $24.9K | 54 | 6.3% |
| Food and Beverage | $12.2K | 100 | 3.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $375,475.74 (94.6%) of $396,818.12 in this company's General Payments records across 85 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Osteoremedies, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Robert Meneghini
$143,166.40 across 23 reported transactions
- 2
Bryan Springer
$76,278.94 across 12 reported transactions
- 3
Scott Sporer
$73,022.20 across 4 reported transactions
- 4
Stephen Incavo
$72,783.85 across 4 reported transactions
- 5
James Browne
$10,224.35 across 24 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Osteoremedies, LLC's spend rank (#825 of 1,925, top 43% by spend) and concentration rank (#679 of 1,838, top 37% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- DeRoyal Industries, Inc. : $17.5K total payments, HHI 2374
- AGEPHA Pharma FZ LLC : $93.7K total payments, HHI 2373
- Access Vascular Inc : $27.0K total payments, HHI 2373
- FloSpine LLC : $48.7K total payments, HHI 2372
- RedDress USA, Inc. : $184.0K total payments, HHI 2360
- Cornerstone Specialty Network LLC : $120.5K total payments, HHI 2356
- Osteoremedies, LLC (this company) : $396.8K total payments, HHI 2355
- Avertix Medical, Inc : $164.0K total payments, HHI 2352
- Ricoh USA, Inc. : $336.00 total payments, HHI 2347
- Human Regenerative Technologies : $64.8K total payments, HHI 2346
- Medical Microinstruments, Inc. : $113.0K total payments, HHI 2343
- Captiox LLC : $34.7K total payments, HHI 2342
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Osteoremedies, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Osteoremedies, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Osteoremedies, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Osseus Fusion Systems, LLC
Lucid Diagnostics Inc.
BrioHealth Solutions, Inc.
Agfa HealthCare Corporation
Molnlycke Health Care US, LLC
Put this to use
Osteoremedies, LLC ranks #825 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Osteoremedies, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.